NCT06038422

GTP Regimen in the Treatment of Refractory/Recurrent HLH

Clinical Study on Efficacy and Safety of GTP Regimen in the Treatment of Refractory/Recurrent Hemophagocytic Lymphohistiocytosis

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Beijing Friendship Hospital · Academic / Other
• Sex: All
• Age: 1 Month
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn about efficacy and safety of GTP regimen in refractory/recurrent hemophagocytic lymphohistiocytosis. The main questions it aims to answer are: * Overall remission rate of GTP regimen in R/R HLH * Adverse effect of GTP regimen Participants will be treated with GTP regimen

Detailed description

Refractory/recurrent hemophagocytic lymphohistiocytosis will be treated with emapalumab combined with teniposide and methylprednisolone. Observed the overall response rate and side effects.

Conditions

• Refractory
• Recurrence
• Hemophagocytic Lymphohistiocytosis

Interventions

Type	Name	Description
DRUG	GTP regimen	Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)

Timeline

• Start date: 2023-09-15
• Primary completion: 2024-09-15
• Completion: 2025-09-15
• First posted: 2023-09-14
• Last updated: 2023-09-14